Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Oklahoma judge approves Teva's $85 million opioid settlement

Published 06/24/2019, 04:42 PM
Updated 06/24/2019, 04:42 PM
© Reuters. FILE PHOTO: The logo of Teva Pharmaceutical Industries is seen during a news conference in Tel Aviv

By Nate Raymond

(Reuters) - An Oklahoma judge on Monday approved a revised $85 million settlement with Teva Pharmaceutical Industries (NYSE:TEVA) Ltd resolving claims by the state's attorney general that the drugmaker helped fuel the U.S. opioid epidemic.

The decision by Cleveland County District Judge Thad Balkman in Norman, Oklahoma came after the state's attorney general, governor and top lawmakers resolved a dispute over how the money should be deposited and spent.

Oklahoma Attorney General Mike Hunter struck an initial settlement with Teva on May 26, just days before the Israel-based drugmaker was set to face trial alongside Johnson & Johnson (NYSE:JNJ), which is continuing to fight the case.

The settlement resolved claims that Teva and other drugmakers helped cause the epidemic by marketing opioids as safe and effective for everyday pain while downplaying their addictive qualities.

The case is one of around 2,000 by state and local governments seeking to hold drugmakers responsible for an epidemic the U.S. Centers for Disease Control and Prevention says led to a record 47,600 opioid-related overdose deaths in 2017.

Teva's deal came just days before the Israel-based drugmaker was set to face trial in the case, and two days after Oklahoma Governor Kevin Stitt signed a bill into law that required funds recovered in lawsuits by the state to be deposited into the state's treasury.

The law followed criticism by state legislators that money from an earlier, $270 million settlement in the case with Purdue Pharma LP in March was not deposited in the state's coffers for lawmakers to determine its use.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Instead, nearly $200 million of that March settlement went toward creating an addiction treatment and research center at Oklahoma State University.

Under Teva's initial settlement, the $85 million was to be deposited into a court-controlled account pending the outcome of J&J's trial.

Hunter's office argued Teva's settlement should be combined with any money J&J must pay to help remedy, or abate, what the state says is a public nuisance that will cost $17.5 billion to remedy over 30 years. J&J denies the allegations.

But Stitt and Republican leaders of the state's legislature argued any funds should be deposited directly with the state's treasury.

Under the revised accord, money from Teva's settlement would be deposited in a fund with the state and only be used to address the opioid epidemic, subjected to future legislation, according to court papers. Teva did not admit wrongdoing.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.